跳至主要内容
临床试验/NCT03886402
NCT03886402撤回不适用

Use of Autologous Adipose-derived Stromal Vascular Fraction to Treat Erectile Dysfunction - A Safety and Feasibility Study

GID BIO, Inc.2 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2021年10月最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
GID BIO, Inc.
入组人数
8
试验地点
2
主要终点
Adverse Events

研究概览

简要总结

This study will examine the safety and feasibility of a single injection of autologous adipose-derived stromal vascular fraction to treat erectile dysfunction.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • history of ED of at least 3 months' duration
  • have been taking a Phosphodiesterase type 5 (PDE5) inhibitor for at least 1 month prior and willing to stop taking any PDE5 inhibitor for duration of study
  • have an IIEF-EF domain score that is ≥11 and ≤25
  • have the same sexual partner for the duration of the study
  • subject and partner willing to voluntarily give consent
  • speak, read and understand English

排除标准

  • non-responders to PDE5 inhibitor
  • radical prostatectomy or other pelvic surgery or penile implant
  • currently taking blood thinners, cancer drugs or HIV drugs
  • allergic to lidocaine, epinephrine, valium
  • diminished decision-making capacity
  • use of tobacco
  • previous pelvic or abdominal radiation therapy
  • anti-androgen therapy
  • untreated hypogonadism
  • uncontrolled hypertension or hypotension
  • unstable cardiovascular disease
  • systemic autoimmune disorder

结局指标

主要结局

Adverse Events

时间窗: 1 year

Monitoring of adverse events

次要结局

  • International Index of Erectile Function (IIEF)(Pre-treatment, 30 days, 3 months and 6 months)

研究者

发起方
GID BIO, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验